PMC:4939752 / 27478-29105 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/4939752","sourcedb":"PMC","sourceid":"4939752","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4939752","text":"Conclusion\nIn conclusion over the last 10 years rituximab is used against the treatment of all common B-cell malignancies. Based on this success, limitations and elucidation of the mechanism various novel anti-CD20 mAbs has been developed to improved clinical outcomes with outstanding performance in ADCC, CDC and PCD and reduced immunogenicity. Although, the mechanisms of action of each anti-CD20 mAbs has been well studied in preclinical settings. However, the variability seen in clinical responses of these mAbs may be depend on level of CD20 expression, levels of circulating soluble CD20, presence of effector cells, CD20 binding epitope and kinetics, binding with Fc receptors, tissue distribution and tumor burden. Singh et al. recently published a report provide information that sub-lethal dose of radiation can induced CD20 surface levels on cells determined efficacy of both type I (rituximab) and type II (tositumomab) anti-CD20 mAbs in vitro. However, more preclinical and clinical investigations need to be confirmed. Therefore, the ability to selectively control CD20 expression and appropriate modifications in Fc domain of mAbs may be great importance in enhancing therapeutic values and in optimizing anti-CD20 immunotherapy and radio-immunotherapy. The modulation in CD20 expression may provide more binding sites for anti-CD20 mAbs and may play a major role in therapeutic response. Based on this information and previous data we suggested that use of external beam radiotherapy (in a site selective manner) just prior to immunotherapy may be beneficial for tumor clearance and maximum clinical outcomes.","divisions":[{"label":"title","span":{"begin":0,"end":10}}],"tracks":[]}